Regulation of Dietary Supplements and Other Specialized Categories The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Pure The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Heard about BPC 157 in health and wellness products? Think it's a "miracle" peptide? Think again. Claims about BPC 157 are based on lab or animal studies, NOT human clinical studies.